GPT and Hyperbilirubinemia: At the recommended 80 mg once-daily continuous dosing schedule for future human efficacy studies, reversible thrombocytopenia (16% of patients) and elevation of alanine transaminase (ALT)/hyperbilirubinemia (5% of patients) were the major dose-limiting toxicities observed in the study.